YD Bio (YDES) Retained Earnings (2024 - 2025)
YD Bio (YDES) posted quarterly Retained Earnings of $213.9 billion for Q4 2025, up 374.65% year-over-year from $45.1 billion in Q4 2024, and up 46552457.02% quarter-over-quarter from $459558.0 in Q2 2025.
YD Bio (YDES) Retained Earnings (2024 - 2025) Analysis & Trends
YD Bio (YDES) has reported Retained Earnings for 2 consecutive years, with $213.9 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings rose 374.65% year-over-year to $213.9 billion; the TTM figure through Dec 2025 stood at $213.9 billion (up 374.65% YoY), while the FY2025 annual figure was $213.9 billion, up 374.65% from the prior year.
- Retained Earnings grew to $213.9 billion in Q4 2025 per YDES's latest filing, from $459558.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $213.9 billion in Q4 2025 and bottomed at $459558.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | YD Bio | 314.91 Mn | 308.91 Mn | - | -10,238.36 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 213.94 Bn |
| Jun 30, 2025 | 459,558.00 |
| Dec 31, 2024 | 45.07 Bn |